Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1CNS 1

Conditions

Medulloblastoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Advanced Fallopian Tube Carcinoma 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Diphtheria-Tetanus Vaccine × Clear all
NCT05096481 2026-05-11

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Nationwide Children's Hospital

Phase 2 Recruiting
120 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Medulloblastoma

NCT06639074 2025-10-02

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Mayo Clinic

Phase 2 Recruiting
78 enrolled
GynecologicSarcoma

Advanced Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡